Celltrion expands Japan push with SteQeyma IV launch

Celltrion said Friday it has launched the intravenous formulation of SteQeyma for autoimmune diseases in Japan. Celltrion launched the IV formulation about four months after receiving approval from Japan’s Ministry of Health, Labour and Welfare in April. In addition to its existing indications for psoriasis and psoriatic arthritis, the product now also covers Crohn’s disease, significantly expanding its treatment scope. Celltrion’s Japanese subsidiary plans to leverage its sales expertise built

By The Korea Herald